elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Zoledronic acid
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Zoledronic acid
RIS
0.001
(Research Intensity Score)
Papers
149
Top papers
Nanozyme‐Reinforced Hydrogel Spray as a Reactive Oxygen Species‐Driven Oxygenator to Accelerate Diabetic Wound Healing
2025 · 88 citations
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
2022 · 268 citations
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
2025 · 44 citations
Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis
2022 · 118 citations
Microenvironment-responsive multifunctional enzyme-linked hydrogel for diabetic bone defect regeneration
2025 · 30 citations
Newest papers
Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis
2026
What is the stability of zoledronic acid when diluted in 100 mL of sodium chloride and stored in a refrigerator?
2026
What is the stability of zoledronic acid when diluted in 100 mL of sodium chloride and stored in a refrigerator?
2026
Marked Parathyroid Hormone (PTH)-Independent Hypercalcemia Revealing Sarcoidosis Mimicking Malignancy: A Case Report
2026
Bone Health in Prostate Cancer: Two Clinical Paradigms and the Evolving Role of Bone-Protecting Agents
2026
A sample from the 100 top papers behind Zoledronic acid.
Create a free account to browse them all →
Zoledronic acid's history
Research intensity over time
Explore Zoledronic acid's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Zoledronic acid's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link